DTIL
Precision Biosciences Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Precision Biosciences Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Linked news
SentenceAlthough Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.
SentenceAdditionally, we do not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from Cellectis.
DTIL 10-Kaccession 0001628280-26-017019
SentenceFor example, our license agreement (the "Duke License") with Duke University ("Duke") imposes various payment, royalty and other obligations on us in order to maintain the license.
DTIL 10-Kaccession 0001628280-26-017019
SentenceAdditionally contributing to the decrease in revenue was $9.5 million of revenue recognized under the TG License Agreement and the Caribou Biosciences, Inc. license agreement in the prior year.
DTIL 10-Kaccession 0001628280-26-017019
SentenceAdditionally on August 15, 2023, we and Imugene US entered into a license agreement (the "Imugene License Agreement"), pursuant to which we granted Imugene US certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize oncological applications of our allogeneic CAR T therapy, azer-cel, and up to three additional research product candidates directed to targets that Imugene US may nominate prior to the fifth anniversary of the effective date of the Imugene License Agreement, pursuant to the terms of the Imugene License Agreement.
DTIL 10-Kaccession 0001628280-26-017019
SentenceOn October 31, 2025, we received an $8.0 million milestone payment from Imugene, comprised of $3.0 million in cash and $5.0 million in Imugene stock.
DTIL 10-Kaccession 0001628280-26-017019
SentenceFor example, we waived earned, but unpaid, milestone payments in connection with the termination of the development and commercial license agreement by and between Les Laboratoires Servier and Institut de Recherches Internationales, Servier (collectively "Servier").
DTIL 10-Kaccession 0001628280-26-017019
SentenceIn July 2022, we received a $50.0 million upfront cash payment under the Novartis Agreement.
DTIL 10-Kaccession 0001628280-26-017019
SentenceThe decrease of $34.4 million in revenue during the year ended December 31, 2025 was primarily the result of $52.7 million of revenue recognized in the prior period related to the conclusion of our agreement with Prevail Therapeutics, which represented all remaining deferred revenue under that agreement.
DTIL 10-Kaccession 0001628280-26-017019
SentenceOn January 7, 2024, we entered into a license agreement (the "TG License Agreement") with TG Cell Therapy, Inc. ("TG Subsidiary") and its parent company TG Therapeutics, Inc. ("TG Parent" and, together with TG Subsidiary, "TG Therapeutics"), pursuant to which we granted TG Subsidiary certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize azercabtagene zapreleucel ("azer-cel") for autoimmune diseases and other indications outside of cancer.
DTIL 10-Kaccession 0001628280-26-017019
SentenceOn January 7, 2024, we entered into a license agreement (the "TG License Agreement") with TG Cell Therapy, Inc. ("TG Subsidiary") and its parent company TG Therapeutics, Inc. ("TG Parent" and, together with TG Subsidiary, "TG Therapeutics"), pursuant to which we granted TG Subsidiary certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize azercabtagene zapreleucel ("azer-cel") for autoimmune diseases and other indications outside of cancer.
DTIL 10-Kaccession 0001628280-26-017019
Precision Biosciences has 3 disclosed suppliers and 9 disclosed customers in SEC filings.
Precision Biosciences Inc
7.07
Expected move
Inputsspot 7.06exp Nov 20ATM strike 7.5ATM straddle 5.35IV 399%